Mergers & Acquisitions ·
AbbVie completed its acquisition of Apogee Therapeutics on September 3, 2026
ABBVAbbVie Inc.
AbbVie completed its acquisition of Apogee Therapeutics on September 3, 2026. Under the agreement, Apogee shareholders received $135.11 per share in cash for a total equity value of approximately $10.9 billion. The transaction adds late-stage assets zumilokibart (APG777) and APG273 to AbbVie's immunology pipeline targeting atopic dermatitis, asthma, and COPD. AbbVie expects the acquisition to dilute adjusted diluted EPS by $0.14 in 2026 and approximately $0.46 in 2027, with accretion beginning in 2032. The company reaffirmed its full-year 2026 adjusted diluted EPS guidance of $13.87 to $14.07 and third-quarter guidance of $3.84 to $3.88. AbbVie is a pharmaceutical company focused on immunology, neuroscience, oncology, and aesthetics.